This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2019
  • /
  • 03
  • /
  • Santhera update on filing for conditional marketin...
Drug news

Santhera update on filing for conditional marketing authorization in Europe for Puldysa (idebenone) in Duchenne Muscular Dystrophy.

Read time: 2 mins
Last updated:1st Apr 2019
Published:30th Mar 2019
Source: Pharmawand

Santhera has expanded and substantiated its previous regulatory dossier with additional clinical data from patients treated with idebenone, new analyses of previously submitted data and new comprehensive natural history data, addressing requests from regulatory authorities. In its entirety, these new data demonstrate clinically relevant patient benefits and sustained therapeutic efficacy during treatment with idebenone for up to six years in patients with DMD.

The new data package and filing strategy have been discussed in several pre-submission meetings with national regulatory authorities.The initial indication intended for Puldysa is to treat respiratory dysfunction in patients with DMD who are not using glucocorticoids. The filing will be based on data from Santhera's Phase II (DELPHI) study, the long-term DELPHI-Extension study, the pivotal Phase III (DELOS) study and the recently completed SYROS study, a collection of long-term data from patients who completed the DELOS study and continued to be treated with idebenone for up to six years .

Key data included in the forthcoming filing : Clinical trial data demonstrate therapeutic potential for idebenone in the treatment of respiratory dysfunction in patients with DMD. Pivotal data from the Phase III (DELOS) study, which met its primary endpoint, demonstrated clinically relevant treatment effects of idebenone compared to placebo on respiratory function outcomes. Supportive evidence comes from the Phase II (DELPHI) study and its two-year open label extension study (DELPHI-E). Idebenone has the potential to delay the time to clinically relevant milestones of disease progression. Peak expiratory flow as percent predicted (PEF%p) is a sensitive and early marker of respiratory function decline in DMD. Analysis of natural history data showed that the treatment benefit observed with idebenone in the DELOS study on PEF%p could, when extrapolated, result in a delay in the initiation of assisted ventilation by three years with continued treatment, which is of high clinical relevance. The beneficial treatment effects of idebenone are sustained year on year for up to six years. The annualized decline in forced vital capacity percent predicted (FVC%p) and PEF%p remained consistently lower for a period of up to six years compared to data from a matched group of untreated patients enrolled in the CINRG natural history study. This long-term data from the SYROS study further support the potential for idebenone to modify the course of respiratory function decline and delay the time to clinically relevant milestones.

Idebenone has been shown to support preservation of respiratory function. Treatment with idebenone also reduced the risk of important patient-relevant outcomes, including bronchopulmonary adverse events and hospitalizations due to respiratory causes as demonstrated in the pivotal study (DELOS) and maintained in the long-term data collection (SYROS).

Comment:The regulatory path of a conditional marketing authorization requires a full dossier with a new tradename, Puldysa , to distinguish this product from Raxone which was previously approved as treatment for patients with Leber's hereditary optic neuropathy.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.